Search
New York Paid Clinical Trials
A listing of 4476 clinical trials in New York actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
4189 - 4200 of 4476
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
New York is currently home to 4476 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruiting
This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
The study will be done in three parts. Part 1a (Monotherapy Dose Escalation) of this study is designed to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of orally administered BTX-A51 in up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
Recruiting
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/19/2024
Locations: Vanda Investigational Site, Brooklyn, New York
Conditions: Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Recruiting
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer.
The names of the potential treatments involved in this study are:
* Active surveillance
* FOLFIRI treatment
* Nivolumab treatment
* Encorafenib/Binimetinib/Cetuximab treatment
* Trastuzumab + Pertuzumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Metastatic Colon Cancer, Stage III Colon Cancer
Metastatic Tumor Research and Outcomes Network
Recruiting
The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Metastatic Spine Tumor
Primary Tumor Research and Outcomes Network
Recruiting
This project aims to establish a network of spine oncology centers dedicated to prospective multicenter research of patients diagnosed with a primary tumor of the spine and will include a comprehensive prospective clinical database which will serve as a shared research platform. Demographic, clinical, diagnostic, and therapeutic variables will be used to answer questions about survival and local recurrence, as well as questions about adverse events (AEs), morbidity data, and health-related quali... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/19/2024
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Spinal Column Tumor
Survivor Mom Companion Comparison Study
Recruiting
The overall goal of the SMC is to help reduce posttraumatic stress symptomology for pregnant persons with a history of trauma.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Buffalo Prenatal-Perinatal Network, Buffalo, New York
Conditions: Posttraumatic Stress Symptom
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
Recruiting
This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
Recruiting
This investigation will be conducted as an interventional intention-to-treat clinical study in a population of end stage heart failure patients who meet specific inclusion and exclusion criteria. The multi-center study will be prospective, dual-armed, non-blinded (open-label) and randomized, comparing a treatment group receiving the Jarvik 2000 LVAS with Post-Auricular Connector to an active control group treated with the PMA approved Thoratec HeartMate® II LVAS for Destination Therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/18/2024
Locations: Columbia/NY Presbyterian, New York, New York
Conditions: Heart Failure
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Recruiting
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer.
The names of the study interventions involved in this study are:
* Radiation Therapy (RT)
* Immunotherapy: Pembrolizumab (MK-3475)
* Chemotherapies:
* Paclitaxel
* Doxorubicin (also called Adriamycin)
* Cyclophosphamide
* Carboplatin (optional, and in TN onl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Recruiting
Infants born prematurely at will be asked to participate in this randomized controlled trial at a corrected gestational age of 24-37 weeks. Infants will be randomly selected to each of the two groups: intervention and control. Infants in the treatment group will receive six intervention days over a two-week period, 3 sessions per week. Each intervention day consists of each of the two interventions in a random sequence: no intervention/silence and live ocean disc instrument intervention. The sou... Read More
Gender:
ALL
Ages:
Between 24 weeks and 37 weeks
Trial Updated:
03/15/2024
Locations: Mount Sinai Hospitals, New York, New York
Conditions: Prematurity
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: COVID-19
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Bronx, New York
Conditions: Neoplasms
4189 - 4200 of 4476
When investigators decide to start a clinical trial, regulatory agencies such as the FDA and the IRB must review all plans and protocols to determine if the proposed trial is safe, ethical, and feasible. All clinical trials that recruit human participants have been reviewed and approved, and both non-paid and paid clinical research studies exist in New York.
After the study is approved the research team sets out to recruit volunteers who would like to participate in a clinical trial. Usually, volunteers are compensated for their time and travel expenses, and many paid clinical trials exist.
While one of the purposes of conducting clinical trials is testing the intervention on a large sample that would be representative of the general population, studies often have inclusion and exclusion criteria that outline who can and cannot participate. The inclusion criteria specifies the characteristics a participant must have in order to participate; for example, a liver cancer trial may have as an inclusion criteria that the participant must be a liver cancer patient.
On the other hand, the exclusion criteria outlines what type of individuals cannot participate; for example, a clinical trial testing a vitamin supplement in healthy individuals might want to disqualify participants who suffer from a serious condition and that can jeopardize the participant's ability to safely receive the experimental intervention. Due to safety concerns, pregnancy is often an exclusion criteria found in many studies.
In New York State, Columbia University and Mount Sinai Hospital are two of the largest research centers conducting clinical trials on a regular basis. As of this month, Columbia University is actively recruiting participants on at least 200 clinical trials from all phases, and Mount Sinai has over 500 active clinical trials.
Search Clinical Trials in New York by Condition
See All Conditions